Eculizumab for severe Covid-19 in the ICU
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This trial tests a drug called eculizumab (also known as Soliris) in people who are in the ICU with severe Covid-19 and a lung condition called ARDS. The drug may help calm an overactive immune response that causes lung damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old
- You must have a confirmed Covid-19 infection
- You must have ARDS, which is a severe lung condition caused by fluid buildup
- You must be in the intensive care unit (ICU)
- You cannot have an active Neisseria infection (a type of bacterial infection)
- You cannot be in another experimental treatment trial for your immune system
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral drug called SPI-1005 for people hospitalized with moderate COVID-19. The drug may help reduce inflammation and protect the lungs, and the study will compare it to a placebo (a pill with no active medicine) to see if it helps people recover.
This trial studies eculizumab, a targeted blood-clotting and immune system medicine, for adults hospitalized with hypertensive emergency–associated hemolytic uremic syndrome (a serious condition affecting kidneys and blood). It aims to see whether the drug can improve outcomes after this life-threatening event.
This trial tests a drug called clazakizumab, which may reduce harmful inflammation in the lungs of people hospitalized with COVID-19. It aims to see if the drug can help patients recover better than a placebo.
This trial tests a new treatment called IC14 for people in the hospital on a breathing machine for ARDS (a severe lung injury). The study aims to see if IC14, which blocks a protein involved in inflammation, can help the lungs heal faster.
This study tests whether starting ravulizumab early, after plasma exchange or IVIg, can help people with a severe myasthenia gravis crisis who are in the intensive care unit. It aims to see if it improves their condition.
This trial tests whether immune-supporting treatment made from exosomes can help people with critically severe COVID-19 and lung damage. If you qualify, you may receive this therapy as part of the study to see if it improves outcomes.
Hear when a new Coronavirus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.